| Autor: |
Hristova-Panusheva K; Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, 'Acad. Georgi Bonchev' Str., Bl. 21, 1113 Sofia, Bulgaria., Xenodochidis C; Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, 'Acad. Georgi Bonchev' Str., Bl. 21, 1113 Sofia, Bulgaria., Georgieva M; Institute of Molecular Biology 'Acad. R. Tsanev', Bulgarian Academy of Sciences, 'Acad. Georgi Bonchev' Str., Bl. 21, 1113 Sofia, Bulgaria., Krasteva N; Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, 'Acad. Georgi Bonchev' Str., Bl. 21, 1113 Sofia, Bulgaria. |
| Abstrakt: |
Nanotechnology has emerged as a transformative force in oncology, facilitating advancements in site-specific cancer therapy and personalized oncomedicine. The development of nanomedicines explicitly targeted to cancer cells represents a pivotal breakthrough, allowing the development of precise interventions. These cancer-cell-targeted nanomedicines operate within the intricate milieu of the tumour microenvironment, further enhancing their therapeutic efficacy. This comprehensive review provides a contemporary perspective on precision cancer medicine and underscores the critical role of nanotechnology in advancing site-specific cancer therapy and personalized oncomedicine. It explores the categorization of nanoparticle types, distinguishing between organic and inorganic variants, and examines their significance in the targeted delivery of anticancer drugs. Current insights into the strategies for developing actively targeted nanomedicines across various cancer types are also provided, thus addressing relevant challenges associated with drug delivery barriers. Promising future directions in personalized cancer nanomedicine approaches are delivered, emphasising the imperative for continued optimization of nanocarriers in precision cancer medicine. The discussion underscores translational research's need to enhance cancer patients' outcomes by refining nanocarrier technologies in nanotechnology-driven, site-specific cancer therapy. |
